NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Gastroenterology and Mucosal Immunity > New therapeutic targets identified to treat inflammatory bowel disease

New therapeutic targets identified to treat inflammatory bowel disease

25 October 2021 · Listed under Gastroenterology and Mucosal Immunity

A new study by University of Oxford researchers has identified potential new therapeutic targets for the treatment of inflammatory bowel disease (IBD), giving hope to millions of patients with ulcerative colitis or Crohn’s disease.

The research team from the University’s Kennedy Institute of Rheumatology and Translational Gastroenterology Unit (TGU) were supported by the NIHR Oxford Biomedical Research Centre (BRC),

Published in Nature Medicine, the research has defined a subset of patients with IBD that do not respond to several current therapies.

The research set out to explore the different cellular and molecular processes that underlie inflammation in the tissue of patients who do not respond to treatment. They found that patients with ulcers who had increased activation of fibroblasts and expansion of the vascular system, and a high number of neutrophils in the inflamed intestine responded poorly to treatments.

Fibroblast activation and accumulation of neutrophils were driven by increased signalling from the cytokine IL-1R, which suggests that blocking IL-1 may benefit those individuals with deep ulceration and who do not respond to several different current therapeutics.

Patients with IBD saw a breakthrough when anti-TNF therapy was shown to be an effective treatment, but up to 40% of patients with IBD don’t respond to the therapy.

“Anti-TNF is not effective in all patients with IBD,” said Professor Fiona Powrie, Director of the Kennedy Institute and lead researcher on the study. “One of the major challenges has been to understand the cellular mechanisms and inflammatory pathways that underlie resistance to treatment in certain individuals but not others. 

“These latest findings are an exciting step forward as they indicate an alternative treatment for a subset of patients who do not respond to current therapies as well as a basis for personalised targeting of medicines to treat this chronic inflammatory condition,” said Prof Powrie (pictured right), the Oxford BRC’s Theme Lead for Gastroenterology and Mucosal Immunity.

Consultant Gastroenterologist Professor Simon Travis of the TGU said: “As a specialist in treating ulcerative colitis and Crohn’s disease, it is hugely exciting to find tools that can help us to select the best possible treatment for each individual.

“This means that we will no longer be in the realm of trial and error, but able to precision-target treatment based on the dominant driver of inflammation in that person.” 

Read more about Prof Powrie’s work.

← New atlas reveals pre-birth development of blood cells in bone marrow
Genetic study highlights links between IBS and mental health disorders →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre